Folic Acid

Folic Acid

SCHEMBL248712

Nc1nc2ncc(CNc3ccc(C(=O)NC(CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1.Nc1nc2ncc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)nc2c(=O)[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TYMS P04818 3/20 1.00
KDM4E B2RXH2 1/20 1.00
MEN1 O00255 1/20 1.00
ALDH1A1 P00352 1/20 1.00
POLB P06746 1/20 1.00
GAA P10253 1/20 1.00
AKR1B1 P15121 1/20 1.00
HPGD P15428 1/20 1.00
TSHR P16473 1/20 1.00
PTGS2 P35354 1/20 1.00
KMT2A Q03164 1/20 1.00
HSD17B10 Q99714 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
ADORA3 P0DMS8 1/20 0.73
DHFR P00374 7/20 0.67
GART P22102 2/20 0.67
ATIC P31939 2/20 0.67
MTHFD1 P11586 1/20 0.57
MTHFD2 P13995 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Folic Acid SCHEMBL29441959 1.00 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL332170 1.00 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL29349485 1.00 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL29388311 1.00 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL16492117 1.00 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL29357550 1.00 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL3877 1.00 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL29624885 1.00 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL403054 1.00 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB
Folic Acid SCHEMBL27730431 1.00 TYMS (1.00) TYMSKDM4EMEN1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2276498-B1 USE OF PROBIOTIC BACTERIA FOR THE TREATMENT OF HYPERHOMOCYSTEINAEMIA PROBIOTICAL SPA (IT) 2016-10-19 EP disclosed
US-20140056987-A1 COMPOSITIONS COMPRISING EXTRACTS OR FRACTIONS DERIVED FROM ANNONA SQUAMOSA FOR THE PREVENTION, TREATMENT OR CONTROL OF INFLAMMATORY AND METABOLIC DISORDERS LAILA NUTRACEUTICALS (IN) 2014-02-27 US disclosed
WO-2012147106-A2 COMPOSITIONS COMPRISING EXTRACTS OR FRACTIONS DERIVED FROM ANNONA SQUAMOSA FOR THE PREVENTION, TREATMENT OR CONTROL OF INFLAMMATORY AND METABOLIC DISORDERS LAILA NUTRACEUTICALS (IN) 2012-11-01 WO disclosed
US-8067416-B2 Methods and compositions for the treatment of metabolic disorders MERCK EPROVA AG (CH) 2011-11-29 US disclosed
US-20110281880-A1 METHODS OF ADMINISTERING TETRAHYDROBIOPTERIN, ASSOCIATED COMPOSITIONS, AND METHODS OF MEASURING BIOMARIN PHARMACEUTICAL INC. (US) 2011-11-17 US disclosed
US-8003126-B2 Storage stability; mixture of tetrahydrobiopterin and excipient BIOMARIN PHARMACEUTICAL INC. (US) 2011-08-23 US disclosed
US-7947681-B2 Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring BIOMARIN PHARMACEUTICAL INC. (US) 2011-05-24 US disclosed
US-20110028714-A1 FOLATE MIMETICS AND FOLATE-RECEPTOR BINDING CONJUGATES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-02-03 US disclosed
US-7875612-B2 diagnostic agent comprising a contrast agent for use in medical imaging conjugated with non-peptide folic acid analog PURDUE RESEARCH FOUNDATION (US) 2011-01-25 US disclosed
WO-2000013502-A1 FOLIAR FERTILIZER AND METHOD FOR USING THE SAME YAMASHITA THOMAS T (US) 2000-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281880-A1 METHODS OF ADMINISTERING TETRAHYDROBIOPTERIN, ASSOCIATED COMPOSITIONS, AND METHODS OF MEASURING VIP, BDKRB2, BDKRB1 TYMS 907/4885KDM4E 4808/4885MEN1 687/4885
US-20140056987-A1 COMPOSITIONS COMPRISING EXTRACTS OR FRACTIONS DERIVED FROM ANNONA SQUAMOSA FOR THE PREVENTION, TREATMENT OR CONTROL OF INFLAMMATORY AND METABOLIC DISORDERS TNF, IL6, MT-ATP6 TYMS 741/4885KDM4E 4370/4885MEN1 3050/4885
US-20110028714-A1 FOLATE MIMETICS AND FOLATE-RECEPTOR BINDING CONJUGATES THEREOF FOLR1, FOLR2, DHFR TYMS 20/4885KDM4E 3935/4885MEN1 1118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.